Literature DB >> 33681215

Caldesmon: Biochemical and Clinical Implications in Cancer.

Yi-Bo Yao1, Chang-Fang Xiao1, Jin-Gen Lu2, Chen Wang1.   

Abstract

Caldesmon, an actin-binding protein, can inhibit myosin binding to actin and regulate smooth muscle contraction and relaxation. However, caldesmon has recently attracted attention due to its importance in cancer. The upregulation of caldesmon in several solid cancer tissues has been reported. Caldesmon, as well as its two isoforms, is considered as a biomarker for cancer and a potent suppressor of cancer cell invasion by regulating podosome/invadopodium formation. Therefore, caldesmon may be a promising therapeutic target for diseases such as cancer. Here, we review new studies on the gene transcription, isoform structure, expression, and phosphorylation regulation of caldesmon and discuss its clinical implications in cancer.
Copyright © 2021 Yao, Xiao, Lu and Wang.

Entities:  

Keywords:  actin binding protein; caldesmon; cancer; isoform; smooth muscle

Year:  2021        PMID: 33681215      PMCID: PMC7930484          DOI: 10.3389/fcell.2021.634759

Source DB:  PubMed          Journal:  Front Cell Dev Biol        ISSN: 2296-634X


  3 in total

1.  MIR100HG Regulates CALD1 Gene Expression by Targeting miR-142-5p to Affect the Progression of Bladder Cancer Cells in vitro, as Revealed by Transcriptome Sequencing.

Authors:  Sheng Zhang; Qin Wang; Wenfeng Li; Jinzhong Chen
Journal:  Front Mol Biosci       Date:  2022-01-21

2.  Caldesmon controls stress fiber force-balance through dynamic cross-linking of myosin II and actin-tropomyosin filaments.

Authors:  Shrikant B Kokate; Katarzyna Ciuba; Vivien D Tran; Reena Kumari; Sari Tojkander; Ulrike Engel; Konstantin Kogan; Sanjay Kumar; Pekka Lappalainen
Journal:  Nat Commun       Date:  2022-10-13       Impact factor: 17.694

3.  CALD1 Modulates Gliomas Progression via Facilitating Tumor Angiogenesis.

Authors:  Quan Cheng; Anliu Tang; Zeyu Wang; Ning Fang; Zhuojing Zhang; Liyang Zhang; Chuntao Li; Yu Zeng
Journal:  Cancers (Basel)       Date:  2021-05-30       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.